GLP-1: benefits beyond pancreas. 2014

G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
Section of Endocrinology, Department of Clinical Medicine and Surgery, University "Federico II", Via Sergio Pansini, 5, Naples, Italy, giovanna.muscogiuri@gmail.com.

BACKGROUND Glucagon-like peptide 1 (GLP-1) is an intestinal hormone secreted after the ingestion of various nutrients. The main role of GLP-1 is to stimulate insulin secretion in a glucose-dependent manner. However, the expression of GLP-1 receptor was found to be expressed in a variety of tissues beyond pancreas such as lung, stomach, intestine, kidney, heart and brain. Beyond pancreas, a beneficial effect of GLP-1 on body weight reduction has been shown, suggesting its role for the treatment of obesity. In addition, GLP-1 has been demonstrated to reduce cardiovascular risk factors and to have a direct cardioprotective effect, fostering heart recovery after ischemic injury. Further, data from both experimental animal models and human studies have shown beneficial effect of GLP-1 on bone metabolism, either directly or indirectly on bone cells. METHODS We review here the recent findings of the extra-pancreatic effects of GLP-1 focusing on both basic and clinical studies, thus opening future perspectives to the use of GLP-1 analogs for the treatment of disease beyond type 2 diabetes. CONCLUSIONS Finally, the GLP-1 has been demonstrated to have a beneficial effect on both vascular, degenerative diseases of central nervous system and psoriasis.

UI MeSH Term Description Entries
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D052216 Glucagon-Like Peptide 1 A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake. GLP-1,Glucagon-Like Peptide-1,GLP 1,Glucagon Like Peptide 1

Related Publications

G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
April 2024, JAAPA : official journal of the American Academy of Physician Assistants,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
September 2008, Circulation. Heart failure,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
April 2024, Discovery medicine,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
February 2018, Diabetes,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
January 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.],
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
January 2023, Current medicinal chemistry,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
January 2021, Frontiers in endocrinology,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
December 2023, Reviews in endocrine & metabolic disorders,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
January 2017, Frontiers in physiology,
G Muscogiuri, and A Cignarelli, and F Giorgino, and F Prodam, and F Prodram, and D Santi, and G Tirabassi, and G Balercia, and R Modica, and A Faggiano, and A Colao
March 2017, Expert opinion on drug safety,
Copied contents to your clipboard!